Cilia appear in a wide variety of cell types, including osteoclasts and osteoblasts, where they function as physiologic and biochemical sensors.
Cilia appear in a wide variety of cell types, including osteoclasts and osteoblasts, where they function as physiologic and biochemical sensors.
Christopher Jacobs, PhD, from Columbia University, discussed the interplay between mechanobiology and biomechanics in primary cilia at the 2014 American Society of Bone and Mineral Research Conference in Houston, Texas.
Individual cells and cell types encounter the outside world differently. Osteoclasts and osteoblasts react to outside forces imposed on them by activities such as strain, exercise, and sitting. Endothelial cells respond to the mechanical stress caused by laminar blood flow, and cellular mechanical transduction is at the center of atherosclerosis.
Primary cilia are single antenna-like structures emerging from each cell. As Dr Jacobs said, “they are not vestigial, not the appendix of the cell.” They specifically function as physiologic and biochemical sensors in cells as diverse as cholangiocytes, osteocytes, and chondrocytes.
In bone, primary cilia function in bone transduction and the lack of cilia interferes with PGE2 release in osteoblasts.
In his talk, Dr Jacobs said that biomechanical changes in the environment alter how the cell can use the cilium as a biochemical sensor. Primary cilia deflect with flow. As a cilium experiences variable timing and force of the flowing air or liquid to which it is exposed, it may change its organization and remodel as it bends.
The microtubular network anchoring the base of cilium becomes enhanced, and this sub-cellular structure seems to be a sensor that adapts to its environment. Primary cilia stiffness can be modulated, as can torsional stiffness. Increased stiffness correlates with the degree of biomechanical sensitivity.
According to Dr Jacobs, future directions for the study of cilia include answering questions about the nature of calcium and other biochemical channels in cilia compared with other cell types. He is also exploring the role of cilia in mesenchymal stem cells.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Diving Deep Into Specialty Pharmacy: Insights and Forecasts From IQVIA’s Doug Long
May 1st 2024Doug Long, MBA, vice president of industry relations at IQVIA, covered a bevy of stakeholder investment–related topics in his presentation at AXS24 on trends in specialty pharmacy, chief among them challenges facing the industry, obesity medications, generics and biosimilars, new product launches, and the outlook for the US market.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More
Forging a Patient-Centric Path to Revolutionize and Redefine Value-Based Care
April 30th 2024Optum Life Sciences and Takeda Pharmaceuticals are partnering on an innovative virtual care pilot program for inflammatory bowel disease meant to both continue the mission of the current value-based health care landscape and raise the bar for personalized care delivery optimization.
Read More